AHRQ (Agency for Healthcare Research and Quality) casts doubt on TMR/PMR (transmyocardial revascularisation)/(percutaneous myocardial revascularisation) for angina
This article was originally published in Clinica
A new Medicare-commissioned technology assessment is highly critical of transmyocardial revascularisation (TMR) and percutaneous myocardial revascularisation (PMR) as a way of treating the crushing pain of angina. The report by the federal Agency for Healthcare Research and Quality (AHRQ) was released ahead of an upcoming Medicare Coverage Advisory Committee meeting on TMR and PMR and could induce Medicare to curtail its coverage of the two technologies.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.